miércoles, 23 de mayo de 2018

Cancer Genetics Risk Assessment and Counseling (PDQ®)—Health Professional Version - National Cancer Institute

Cancer Genetics Risk Assessment and Counseling (PDQ®)—Health Professional Version - National Cancer Institute
National Cancer Institute

Cancer Genetics Risk Assessment and Counseling (PDQ®)–Health Professional Version




SECTIONS

Changes to This Summary (05/16/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Revised text to state that the use of a patient navigator or an oncology clinic–based genetic counselor may increase utilization of genetic counseling services (cited Kentwell et al. as reference 24).
This section was comprehensively reviewed and extensively revised.
Added text about a clinical lab that found that 40% of variants reported in direct-to-consumer (DTC) raw data were false positives (cited Tandy-Connor et al. as reference 66). In addition, several variants that were designated as “increased risk” in the raw data were classified as benign by clinical laboratories and public databases. Given the potential for misinterpretation, which may lead to unnecessary medical procedures or testing, these findings underscore the importance of clinical confirmation of all potentially medically actionable gene variants identified by DTC testing.
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: May 16, 2018

No hay comentarios:

Publicar un comentario